Jonathan Cotliar - Net Worth and Insider Trading

Jonathan Cotliar Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Jonathan Cotliar owns 1 companies in total, including Science 37 Holdings Inc (SNCE) .

Click here to see the complete history of Jonathan Cotliar’s form 4 insider trades.

Insider Ownership Summary of Jonathan Cotliar

Ticker Comapny Transaction Date Type of Owner
SNCE Science 37 Holdings Inc 2021-10-06 Chief Medical Officer

Jonathan Cotliar Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Jonathan Cotliar Ownership Network

Ownership Network List of Jonathan Cotliar

No Data

Ownership Network Relation of Jonathan Cotliar

Insider Network Chart

Jonathan Cotliar Owned Company Details

What does Science 37 Holdings Inc do?

Who are the key executives at Science 37 Holdings Inc?

Jonathan Cotliar is the Chief Medical Officer of Science 37 Holdings Inc. Other key executives at Science 37 Holdings Inc include Chief Technology Officer Troy Bryenton , Chief Legal Officer Christine A Pellizzari , and Chief Commercial Officer Michael Shipton .

Science 37 Holdings Inc (SNCE) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Science 37 Holdings Inc (SNCE) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Science 37 Holdings Inc (SNCE) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Science 37 Holdings Inc (SNCE)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Science 37 Holdings Inc Insider Transactions

No Available Data

Jonathan Cotliar Mailing Address

Above is the net worth, insider trading, and ownership report for Jonathan Cotliar. You might contact Jonathan Cotliar via mailing address: C/o Lifesci Acquisition Ii Corp., 250 W 55th Street, #3401, New York Ny 10019.

Discussions on Jonathan Cotliar

No discussions yet.